Melanoma

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Podcasts

Experienced Dermatologists Continue to Outperform Artificial Intelligence in Skin Cancer Diagnosis

08/04/2026

Luc Thomas, MD, PhD

Luc Thomas, MD, PhD, discusses findings from a real-world study comparing artificial intelligence models with clinicians for skin cancer diagnosis, highlighting the strengths and limitations of artificial intelligence and reinforcing the...

Luc Thomas, MD, PhD, discusses...

08/04/2026

Oncology

Videos

Neoadjuvant Nivolumab Plus Relatlimab Produces Deep Responses in High-Risk Melanoma

06/19/2026

Georgina Long, MBBS, PhD

Georgina Long, MD, PhD, discusses results from the phase 2 NEO-RENI-2 trial showing that neoadjuvant nivolumab plus relatlimab achieved a 60% pathologic complete response rate and 65% major pathologic response rate in patients with resectable...

Georgina Long, MD, PhD,...

06/19/2026

Oncology

Videos

Novel Neoadjuvant Approach Expands Treatment Options for Patients With Melanoma

06/18/2026

Katharina Kaehler, MD

Katharina Kaehler, MD, discusses updated results from the phase 3 PIVOTAL trial showing that neoadjuvant intralesional immunotherapy significantly improved relapse-free, distant metastasis-free, and event-free survival compared with upfront...

Katharina Kaehler, MD, discusses...

06/18/2026

Oncology

Videos

Darovasertib Plus Crizotinib Combination Demonstrates Meaningful Clinical Benefit in Metastatic Uveal Melanoma

06/15/2026

Marlana Orloff, MD

Marlana Orloff, MD, discusses results from the phase 2 OPTIMUS-2 trial showing that darovasertib plus crizotinib significantly improved progression-free survival, response rates, and disease control compared with investigator’s choice therapy...

Marlana Orloff, MD, discusses...

06/15/2026

Oncology

Videos

Adjuvant Pembrolizumab Reduces Distant Recurrence Risk in Merkel Cell Carcinoma

06/12/2026

Janice Mehnert, MD

Janice Mehnert, MD, discusses updated phase 3 STAMP trial results showing that adjuvant pembrolizumab improved distant metastasis-free survival in patients with surgically treated Merkel cell carcinoma, while exploratory analyses suggested...

Janice Mehnert, MD, discusses...

06/12/2026

Oncology

Videos

Immune Modulatory Vaccine Plus Pembrolizumab for First-Line Treatment of Patients With Advanced Melanoma

10/30/2025

Jessica Hassel, MD

Jessica Hassel, MD, shares results from a phase 3 trial evaluating the IO102-IO103 cancer vaccine in combination with pembrolizumab in the first-line setting for patients with advanced melanoma in the first line.

Jessica Hassel, MD, shares...

10/30/2025

Oncology

Videos

Neoadjuvant Dostarlimab Plus Cobolimab Demonstrates Promise Among Patients With High-Risk Resectable Melanoma

08/12/2025

Meghan Mooradian, MD

Meghan Mooradian, MD, discusses primary analysis results from the phase 2 NEO-MEL-T trial, which showed that neoadjuvant dostarlimab plus cobolimab demonstrated promising efficacy and safety among patients with high-risk resectable melanoma.

Meghan Mooradian, MD, discusses...

08/12/2025

Oncology

Videos

First-Line Encorafenib Plus Binimetinib and Nivolumab for Patients With BRAF-Mutated Melanoma Brain Metastases

07/24/2025

Zeynep Eroglu, MD

Zeynep Eroglu, MD, discusses results from the SWOG S2000 study which demonstrated that encorafenib plus binimetinib and nivolumab significantly improved progression-free survival compared to ipilimumab plus nivolumab among patients with...

Zeynep Eroglu, MD, discusses...

07/24/2025

Oncology

Videos

Addition of Relatimab to Nivolumab Did Not Significantly Improve Outcomes for Patients With Melanoma

07/24/2025

Georgina Long, MBBS, PhD

Georgina Long, MD, PhD, discusses primary results from the RELATIVITY-098 trial, which demonstrated that adjuvant nivolumab plus relatimab did not significantly improve outcomes compared to adjuvant nivolumab monotherapy among patients with...

Georgina Long, MD, PhD,...

07/24/2025

Oncology

Videos

Adjuvant Encorafenib Plus Binimetinib Demonstrates Promise Among Patients With BRAF-Mutated Melanoma

07/24/2025

Alexander Van Akkooi, MD, PhD

Alexander Van Akkooi, MD, PhD, discusses primary analysis results from the EORTC 2139-MG/Columbus-AD trial which demonstrated that adjuvant encorafenib plus binimetinib demonstrates clinical promise among patients with BRAF-mutated melanoma.

Alexander Van Akkooi, MD, PhD,...

07/24/2025

Oncology

Recent News

News

IO102-IO103 Plus Nivolumab and Relatlimab Demonstrates Encouraging Activity in Unresectable Melanoma

08/05/2026

Stephanie Holland

A phase 2 trial demonstrated that the investigational cancer vaccine IO102-IO103 combined with nivolumab and relatlimab achieved a 60% objective response rate in previously untreated unresectable melanoma, supporting further evaluation of the...

A phase 2 trial demonstrated...

08/05/2026

Oncology

News

HBI-8000 Plus Nivolumab Significantly Improves Progression-Free Survival in Advanced Melanoma

08/05/2026

Stephanie Holland

Topline results from a global phase 3 trial demonstrated that HBI-8000 plus nivolumab significantly improved progression-free survival compared with nivolumab alone in patients with advanced melanoma, supporting the combination as a potential...

Topline results from a global...

08/05/2026

Oncology

FDA Approval

FDA Approves Rituximab Biosimilar for the Treatment of B-Cell Malignancies and Autoimmune Diseases

08/04/2026

Stephanie Holland

The FDA has approved a rituximab biosimilar referencing Rituxan for multiple hematologic malignancies and autoimmune diseases. Approval was supported by a comprehensive biosimilar development program demonstrating high similarity and no...

The FDA has approved a rituximab...

08/04/2026

Oncology

FDA Alerts

FDA Advisory Committee Backs RP1 Plus Nivolumab for Advanced Melanoma in 10-3 Vote

07/31/2026

Stephanie Holland

The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10-3 that efficacy findings from the phase 2 IGNYTE trial of RP1 (vusolimogene oderparepvec) plus nivolumab are clinically meaningful, supporting the investigational...

The FDA's Cellular, Tissue, and...

07/31/2026

Oncology

FDA Alerts

Subcutaneous Amivantamab Receives FDA Priority Review for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

07/30/2026

Emily Estrada

The FDA granted Priority Review to subcutaneous amivantamab and hyaluronidase for previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma, supported by results from the phase 1b/2 OrigAMI-4 trial.

The FDA granted Priority Review...

07/30/2026

Oncology

News

Regorafenib Producess High Response and Durable Disease Control in KIT-Mutant Advanced Melanoma

07/29/2026

Stephanie Holland

The phase 2 RegoMel trial demonstrated that continuous daily regorafenib produced clinically meaningful antitumor activity in heavily pretreated advanced melanoma, with particularly high response rates in KIT-mutant disease and encouraging...

The phase 2 RegoMel trial...

07/29/2026

Oncology

News

Ceralasertib Plus Durvalumab Demonstrates Limited Activity in PD-L1-Resistant Advanced Melanoma

07/29/2026

Stephanie Holland

The phase 2 MONETTE trial found that ceralasertib, administered alone or in combination with durvalumab, produced low response rates in patients with anti–PD-L1-resistant advanced melanoma, while exploratory analyses identified higher...

The phase 2 MONETTE trial found...

07/29/2026

Oncology

News

Real-World Study Demonstrates Rapid Pain Relief, Durable Disease Control, and Manageable Safety With Nirogacestat in Young Adults With Desmoid Tumors

07/28/2026

Emily Estrada

A real-world study found that nirogacestat provided rapid pain relief, durable disease control, and a manageable safety profile in young adults with desmoid tumors, supporting its use in routine clinical practice while emphasizing the...

A real-world study found that...

07/28/2026

Oncology

News

Real-World Study Highlights Evolving Treatment Patterns and Petsistent Diagnostic Challenges in Patients With Desmoid Tumors

07/28/2026

Emily Estrada

Real-world findings demonstrated declining use of surgery and increasing adoption of systemic therapies for desmoid tumors, while highlighting substantial symptom burden, frequent treatment changes, and increased healthcare resource...

Real-world findings demonstrated...

07/28/2026

Oncology

News

Real-World Analysis Identifies Performance Status as a Key Predictor of Outcomes With Tarlatamab in Extensive-Stage Small Cell Lung Cancer

07/28/2026

Stephanie Holland

Results from the largest real-world analysis of tarlatamab to date demonstrated that baseline performance status was a major determinant of clinical outcomes in patients with previously treated extensive-stage small cell lung cancer, whereas...

Results from the largest...

07/28/2026

Oncology